The present study shows that, for Singapore Chinese, intake of soy is associated with reduced risk of osteoporotic hip fracture for women but not for men. Total calcium intake from dietary sources and supplements was unrelated to hip fracture risk for men. Although calcium intake showed a statistically significant, positive association with hip fracture risk for women, it was largely confined to those with a relatively short duration of follow-up.
To our knowledge, this prospective cohort study is the first that examines risk factors for osteoporotic hip fracture for both genders in a nonwhite population living in Asia. For many factors, especially those related to diet and lifestyle, exposure ranges widely in this increasingly westernized society in Singapore. Other strengths of the study are its population-based design and the reduced likelihood of recall bias regarding exposure data since they were obtained prior to disease diagnosis. Singapore is a small city-state, with a system for easy access to specialized medical care. Since practically all hip fracture cases will seek medical attention immediately and be hospitalized for surgical hip hemiarthroplasty, our case ascertainment through linkage with the comprehensive, nationwide hospital database can be considered complete. The information from the database also enabled us to differentiate prevalent cases from incident cases using the dates of recruitment into the study and admission to the hospital after the fracture.
Limitations of this study include possible misclassification of soy intake from use of a food frequency questionnaire. However, such misclassifications, if any, are nondifferential and are more likely to result in underestimation of the true hazard risk. Another limitation is the lack of study subjects’ lifetime history of dietary intake. We assessed dietary intakes up to the time of cohort enrollment, which may have been years before hip fracture in our cases. The change in subjects’ dietary habits from the time of baseline assessment to the censoring date could result in attenuation of observed risk estimates for hip fracture associated with dietary factors studied.
The novel finding in this study is the inverse, dose-dependent association between soy and osteoporotic hip fracture risk found for women but not for men. Soy food contains soy isoflavones, which belong to a class of plant compounds called phytoestrogen and may account for the potential bone-protective effects associated with soy food. A meta-analysis of 10 short-term clinical trials involving 608 subjects concluded that oral isoflavone intervention significantly attenuates bone loss of the spine in menopausal women (
26). In fact, as naturally occurring selective estrogen receptor modulators, isoflavones may exert estrogenic effects when the endogenous estrogen level is low, that is, during menopause, and not be effective in premenopausal women.
In support of this possibility is evidence that the more osteopenic the bones are in postmenopausal women, the more effective isoflavone supplementation is in reducing bone loss. A double-blind, placebo-controlled, randomized trial among Chinese women aged 48–62 years showed that the reduction in bone loss from isoflavone supplementation was observed among only those women with lower initial baseline bone mineral content, who were also in later menopause (
20,
27). Consistently, cross-sectional surveys among Chinese women showed that the dose-response relation between higher bone mineral density values of the hip and increasing soy protein intake was observed among postmenopausal but not premenopausal women (
28) and that, among postmenopausal women, the association was stronger for women with a longer duration of postmenopausal status (
19).
Epidemiologic studies of postmenopausal women in Asian populations that consume a soy-rich diet in Japan and Hong Kong have shown that high intake of soy protein is associated with higher bone mineral density, particularly in the hip region (
19,
29). In a recent cohort study involving 24,403 postmenopausal Chinese women in Shanghai (the Shanghai Women's Health Study), hip fracture risk associated with the second and higher quintiles of soy intake (≥5 g/day of soy protein) was 30% lower than that associated with the lowest quintile of intake (
18). The present study also noted a similar threshold effect between soy protein and hip fracture risk. Furthermore, the levels of threshold dose and its corresponding magnitude of risk reduction are comparable across these 2 independently conducted, geographically distinct cohort studies of Asian Chinese women. Thus, the level of soy isoflavones necessary for bone health in women may be much lower than the doses administered to subjects of intervention studies conducted to date (
26).
The effects of soy in preventing osteoporosis in men have not been determined. A controlled, doubled-blind trial of 145 men and women of comparable ages, 50–80 years, in the United States showed that soy protein supplementation had significantly greater effects on spine bone mineral density in women than in men, although there was no significant effect in either gender for hip bone mineral density (
30). Another randomized, controlled trial among middle-aged and elderly men showed that soy protein supplementation did not affect serum bone-specific alkaline phosphatase level, which is considered a biomarker for osteoblastic activity (
31). Such studies in humans are consistent with experimental studies using rodent models, which have shown that neonatal exposure to genistein, a prototype of soy isoflavones, increased bone marrow densities in the femurs and spines of adult female mice but had an effect in only the spines but not the femurs of male mice. The authors had suggested that genistein could have site-specific effects on skeletal health in males and that, although genistein acted as a selective estrogen receptor modulator in females, the mechanism of action of genistein in males was still unclear (
32). Furthermore, other animal studies showing that genistein or soy isoflavones may reduce age-related bone loss by increasing osteoblastic activity in males had been conducted in orchidectomized male rodents. Such animal models are more likely to simulate abrupt and marked male hormonal deficiency (
33–
35) and probably do not reflect the gradual hormonal decline in aging men (
22).
In a large, US study of 2,623 men, the age-related decline in testosterone and estradiol in older men was quite modest, and substantial variation in one hormone existed at any level of the other (
36). Since testosterone is aromatized to estradiol, a feedback mechanism may exist between these hormones in men to maintain bone health in the physiology of aging. Consistent with this hypothesis, studies on elderly men in the Framingham study have shown that the risk of fracture is significantly increased in the subgroup with concomitantly low testosterone and estradiol levels and that both sex hormones may interact to produce a synergistic effect on hip fracture risk in men (
37). If this is the case, soy isoflavone supplementation may not be sufficient to reduce fracture risk for elderly men with concurrently low levels of both hormones.
In our study, current smokers of both genders had about a 20% increase in hip fracture risk, which was lower than the pooled relative risk of 1.39 (95% confidence interval: 1.23, 1.58) from a meta-analysis of 50 independent studies. That meta-analysis also noted that smaller risk ratios were observed in countries closer to the equator relative to those further away from the equator, such as the United States and northern Europe (
38). Singapore is one degree north of the equator, whereas the bulk of the 50 studies in the meta-analysis were conducted in Western countries in the Northern Hemisphere. Thus, our results on tobacco smoking are consistent with the overall findings reported in the literature. Similarly, the inverse relation between body mass index and hip fracture risk in our study concurred with the results from a meta-analysis of 12 population-based cohort studies (
39).
In our study, increased calcium intake or the use of calcium supplements was associated with increased risk of hip fracture for women with less than 5 years of follow-up. Women who had a hip fracture within 5 years after enrollment could have increased their dietary calcium intake and use of calcium supplements at enrollment given the knowledge about their poor bone mineral density or risk of hip fracture. The absence of a positive calcium–hip facture association for both men and women with more than 5 years of follow-up supports our conjecture. Several other longitudinal studies failed to detect any adverse or beneficial effect of dietary calcium on bone loss or hip fracture, further supporting our findings in this study (
11,
40–
44).
In conclusion, we report a novel finding that dietary soy protects against hip fracture in women but not in men. A biologically plausible explanation for this observation has been proposed and warrants further investigation.